SEQUENCE LISTING

<110> EISAI R&D MANAGEMENT CO., LTD.

<120> ANTI-HUMAN XCR1 ANTIBODIES

<130> P12-035

<150> US 61/530194
<151> 2011-09-01

<150> US 61/659637
<151> 2012-06-14

<160> 119

<170> PatentIn version 3.4

<210> 1
<211> 121
<212> PRT
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (2H6) Heavy chain variable region

<400> 1

```
Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
1               5                   10                  15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser His
            20                  25                  30

Asn Met His Trp Ile Lys Gln Thr Leu Arg Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Ala Ile Tyr Pro Gly Lys Gly Asn Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                85                  90                  95

Ala Arg Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val Trp Gly
            100                 105                 110

Thr Gly Thr Thr Val Thr Val Ser Ser
        115                 120
```

<210> 2
<211> 112
<212> PRT
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (2H6) Light chain variable region

<400> 2

Asp Val Val Val Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30

Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Leu Gly Arg Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
85 90 95

Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 3
<211> 363
<212> DNA
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (2H6) Heavy chain variable region

<400> 3
caggcttatc tacagcagtc tggggctgaa ctggtgaggc ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacatttagc agtcacaata tgcactggat aaagcagaca 120

cttagacagg gcctggaatg gataggagct atttatccag gaaaaggtaa tacttcctac 180

aatcagaagt tcaagggcaa ggccacactg actgtagaca aatcctccag cacagcctac 240

atgcagctca gcagcctgac atctgaagac tctgcggtct atttctgtgc aagatggggt 300

tcggtagtag gagactggta cttcgatgtc tggggcacag ggaccacggt caccgtctct 360

tca 363

<210> 4
<211> 336
<212> DNA
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (2H6) Light chain variable region

<400> 4
gatgttgtgg tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gatctagtca gagccttgta cacagtaatg gaaacaccta tttacattgg 120

tacctgcaga agccaggcca gtctccaaag ctcctgatct acagagtttc caatcgattt 180

tctggggtcc cagacaggtt cagtggcagt ggattaggga gagatttcac actcaagatc 240

agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac atttgttccg 300

tggacgttcg gtggaggcac caagctggaa atcaaa 336

<210> 5
<211> 121
<212> PRT
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (5G7) Heavy chain variable region

<400> 5

Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
20 25 30

Asn Leu His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Gln Trp Ile
35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asn Thr Ala Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val Trp Gly
100 105 110

Thr Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 6
<211> 112
<212> PRT
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (5G7) Light chain variable region

<400> 6

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Asn Gln Ala Ser Ile Phe Cys Arg Ser Ser Leu Gly Leu Val His Arg
20 25 30

Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Lys Val Ser His Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
85 90 95

Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 7
<211> 363
<212> DNA
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (5G7) Heavy chain variable region

<400> 7
caggcttatc ttcagcagtc tggggctgaa ctggtgaggc ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacattcacc agtcacaatt tgcactgggt aaagcagaca 120

cctagacagg gcctgcaatg gattggagct atttatccag gaaatggtaa tactgcctac 180

aatcagaagt tcaagggcaa ggccacgctg actgtagaca aatcctccag tacagcctac 240

atgcagctca gcagcctgac atctgatgac tctgcggtct acttctgtgc aagatggggt 300

tcggttgtag gagactggta cttcgacgtc tggggcacag ggaccacggt caccgtctcc 360

tca 363

<210> 8
<211> 336
<212> DNA
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (5G7) Light chain variable region

<400> 8
gatgttgtga tgacccaaac tccactctcc ctgcctgtca ctcttggaaa tcaagcctcc 60

atttttgta gatctagtct gggccttgta cacagaaatg gaaacaccta tttacattgg 120

tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc ccaccgattt 180

tctggggtcc cagacaggtt cagtggcagt ggctcaggga cagatttcac actcaagatc 240

agcagagtgg aggctgagga tctgggggtt tatttctgct ctcaaagtac ccatgttccg 300

tggacgttcg gtggaggcac caagctggaa atcaaa 336

<210> 9
<211> 122

<212> PRT
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (11H2) Heavy chain variable region

<400> 9

```
Glu Val Gln Leu Gln Gln Ser Gly Pro Val Leu Val Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30


Tyr Val Asn Trp Val Lys Gln Ser His Gly Ala Ser Leu Glu Trp Ile
        35                  40                  45


Gly Val Ser Asn Pro Lys Asn Gly Asp Lys Ser Tyr Asn Gln Lys Phe
    50                  55                  60


Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Gly Leu Tyr Tyr Ala Gly Thr Tyr Gly Tyr Phe Asp Val Trp
            100                 105                 110


Gly Thr Gly Thr Thr Val Thr Val Ser Ser
        115                 120
```

<210> 10
<211> 107
<212> PRT
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (11H2) Light chain variable region

<400> 10

```
Asp Ile Gln Met Thr Gln Ala Thr Ser Ser Leu Ser Ala Ser Leu Gly
1               5                   10                  15


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
            20                  25                  30


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
        35                  40                  45


Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Arg Gly
    50                  55                  60


Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Asn Leu Glu Gln
65                  70                  75                  80
```

Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Lys Thr Leu Pro Arg
85 90 95

Thr Leu Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 11
<211> 366
<212> DNA
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (11H2) Heavy chain variable region

<400> 11
gaggtccagc ttcaacagtc tggacctgtg ctggtgaagc ctggggcttc agtgaagatg 60

tcctgtaagg cttctggata cacattcact gactactatg tgaactgggt gaaacagagc 120

catggagcga gccttgagtg gattggagtt agtaatccta agaacggtga taaaagttac 180

aaccagaagt tcaagggcaa ggccacattg actgttgaca agtcctccag tacagcctac 240

atggagctca acagcctgac atctgaggac tctgctgtct attactgtgc aagagggctt 300

tactacgctg gtacctacgg gtacttcgat gtctggggca cggggaccac ggtcaccgtc 360

tcctca 366

<210> 12
<211> 321
<212> DNA
<213> Artificial

<220>
<223> Mouse Anti-Human XCR1 Antibody (11H2) Light chain variable region

<400> 12
gatatccaga tgacacaggc tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60

atcagttgta gggcaagtca ggacattagc aattatttaa actggtatca gcagaagcca 120

gatggaactg ttaaactcct gatctactac acatcaagat tacactcagg tgtcccatca 180

aggttcagag gcagtgggtc tgggacagat ttctctctca ccattagcaa cctggagcaa 240

gaagatattg ccacttattt ttgccaacag ggtaaaacgc ttcctcggac gctcggtgga 300

ggcaccaagc tggaaatcaa a 321

<210> 13
<211> 447
<212> PRT
<213> Artificial

<220>
<223> Chimeric Anti-Human XCR1 Antibody Heavy chain

<400> 13

Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
1 5 10 15

```
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
            20                  25                  30

Asn Leu His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Gln Trp Ile
        35                  40                  45

Gly Ala Ile Tyr Pro Gly Asn Gly Asn Thr Ala Tyr Asn Gln Lys Phe
    50                  55                  60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80

Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys
                85                  90                  95

Ala Arg Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val Trp Gly
            100                 105                 110

Thr Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
        115                 120                 125

Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
    130                 135                 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145                 150                 155                 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
                165                 170                 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
            180                 185                 190

Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His
        195                 200                 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
    210                 215                 220

Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Ala Ala Ala Pro Ser Val
225                 230                 235                 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
                245                 250                 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
            260                 265                 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
        275                 280                 285
```

```
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser
    290                 295                 300

Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305                 310                 315                 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
                325                 330                 335

Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
            340                 345                 350

Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
        355                 360                 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
    370                 375                 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
385                 390                 395                 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
                405                 410                 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
            420                 425                 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445


<210>  14
<211>  219
<212>  PRT
<213>  Artificial

<220>
<223>  Chimeric Anti-Human XCR1 Antibody Light chain

<400>  14

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly
1               5                   10                  15

Asn Gln Ala Ser Ile Phe Cys Arg Ser Ser Leu Gly Leu Val His Arg
            20                  25                  30

Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45

Pro Lys Leu Leu Ile Tyr Lys Val Ser His Arg Phe Ser Gly Val Pro
    50                  55                  60
```

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
85 90 95

Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 15
<211> 1344
<212> DNA
<213> Artificial

<220>
<223> Chimeric Anti-Human XCR1 Antibody Heavy chain

<400> 15
caggcttatc ttcagcagtc tggggctgaa ctggtgaggc ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacattcacc agtcacaatt tgcactgggt aaagcagaca 120

cctagacagg gcctgcaatg gattggagct atttatccag gaaatggtaa tactgcctac 180

aatcagaagt tcaagggcaa ggccacgctg actgtagaca aatcctccag tacagcctac 240

atgcagctca gcagcctgac atctgatgac tctgcggtct acttctgtgc aagatggggt 300

tcggttgtag gagactggta cttcgacgtc tggggcacag ggaccacggt caccgtctcc 360

tcagctagca ccaagggccc atcggtcttc cccctggcgc cctgctccag gagcacctcc 420

gagagcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg 480

tcgtggaact caggcgctct gaccagcggc gtgcacacct tcccggctgt cctacagtcc 540

tcaggactct actccctcag cagcgtggtg accgtgccct ccagcaactt cggcacccag 600

acctacacct gcaacgtaga tcacaagccc agcaacacca aggtggacaa gacagttgag 660

cgcaaatgtt gtgtcgagtg cccaccgtgc ccagcaccac ctgccgcagc cccgtcagtc 720

ttcctgttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcacg 780

tgcgtggtgg tggacgtgag ccacgaagac cccgaggtcc agttcaactg gtacgtggac 840

ggcgtggagg tgcataatgc caagacaaag ccacgggagg agcagttcaa cagcacgttc 900

cgtgtggtca gcgtcctcac cgtcgtgcac caggactggc tgaacggcaa ggagtacaag 960

tgcaaggtct ccaacaaagg cctcccagcc cccatcgaga aaaccatctc caaaaccaaa 1020

gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag 1080

aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1140

tgggagagca atgggcagcc ggagaacaac tacaagacca cacctcccat gctggactcc 1200

gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg 1260

aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 1320

ctctccctgt ctccgggtaa atga 1344

<210> 16
<211> 660
<212> DNA
<213> Artificial

<220>
<223> Chimeric Anti-Human XCR1 Antibody Light chain

<400> 16
gatgttgtga tgacccaaac tccactctcc ctgcctgtca ctcttggaaa tcaagcctcc 60

atttttgta gatctagtct gggccttgta cacagaaatg gaaacaccta tttacattgg 120

tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc ccaccgattt 180

tctggggtcc cagacaggtt cagtggcagt ggctcaggga cagatttcac actcaagatc 240

agcagagtgg aggctgagga tctgggggtt tatttctgct ctcaaagtac ccatgttccg 300

tggacgttcg gtggaggcac caagctggaa atcaaacgta cggtggctgc accatctgtc 360

ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg 420

ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa 480

tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac ctacagcctc 540

agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa 600

gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgttag 660

<210> 17
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 1 of 5G7

<400> 17

Ser His Asn Leu His
1 5

<210> 18
<211> 17
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 2 of 5G7

<400> 18

Ala Ile Tyr Pro Gly Asn Gly Asn Thr Ala Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> 19
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 3 of 5G7

<400> 19

Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val
1 5 10

<210> 20
<211> 16
<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 1 of 5G7

<400> 20

Arg Ser Ser Leu Gly Leu Val His Arg Asn Gly Asn Thr Tyr Leu His
1 5 10 15

<210> 21
<211> 7
<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 2 of 5G7

<400> 21

Lys Val Ser His Arg Phe Ser
1 5

<210> 22
<211> 9

<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 3 of 5G7

<400> 22

Ser Gln Ser Thr His Val Pro Trp Thr
1 5

<210> 23
<211> 15
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 1 of 5G7

<400> 23
agtcacaatt tgcac 15

<210> 24
<211> 51
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 2 of 5G7

<400> 24
gctatttatc caggaaatgg taatactgcc tacaatcaga agttcaaggg c 51

<210> 25
<211> 36
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 3 of 5G7

<400> 25
tggggttcgg ttgtaggaga ctggtacttc gacgtc 36

<210> 26
<211> 48
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 1 of 5G7

<400> 26
agatctagtc tgggccttgt acacagaaat ggaaacacct atttacat 48

<210> 27
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 2 of 5G7

<400> 27
aaagtttccc accgattttc t 21

<210> 28
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 3 of 5G7

<400> 28
tctcaaagta cccatgttcc gtggacg 27

<210> 29
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 1 of 2H6

<400> 29

Ser His Asn Met His
1 5

<210> 30
<211> 17
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 2 of 2H6

<400> 30

Ala Ile Tyr Pro Gly Lys Gly Asn Thr Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> 31
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 3 of 2H6

<400> 31

Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val
1 5 10

<210> 32
<211> 16
<212> PRT
<213> Artificial

<220>

<223> Light chain CDR 1 of 2H6

<400> 32

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His
1 5 10 15

<210> 33
<211> 7
<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 2 of 2H6

<400> 33

Arg Val Ser Asn Arg Phe Ser
1 5

<210> 34
<211> 9
<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 3 of 2H6

<400> 34

Ser Gln Ser Thr Phe Val Pro Trp Thr
1 5

<210> 35
<211> 15
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 1 of 2H6

<400> 35
agtcacaata tgcac 15

<210> 36
<211> 51
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 2 of 2H6

<400> 36
gctatttatc caggaaaagg taatacttcc tacaatcaga agttcaaggg c 51

<210> 37
<211> 36
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 3 of 2H6

<400> 37
tggggttcgg tagtaggaga ctggtacttc gatgtc 36

<210> 38
<211> 48
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 1 of 2H6

<400> 38
agatctagtc agagccttgt acacagtaat ggaaacacct atttacat 48

<210> 39
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 2 of 2H6

<400> 39
agagtttcca atcgattttc t 21

<210> 40
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 3 of 2H6

<400> 40
tctcaaagta catttgttcc gtggacg 27

<210> 41
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 1 of 11H2

<400> 41

Asp Tyr Tyr Val Asn
1 5

<210> 42
<211> 17
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 2 of 11H2

<400> 42

Val Ser Asn Pro Lys Asn Gly Asp Lys Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> 43
<211> 13
<212> PRT
<213> Artificial

<220>
<223> Heavy chain CDR 3 of 11H2

<400> 43

Gly Leu Tyr Tyr Ala Gly Thr Tyr Gly Tyr Phe Asp Val
1 5 10

<210> 44
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 1 of 11H2

<400> 44

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10

<210> 45
<211> 7
<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 2 of 11H2

<400> 45

Tyr Thr Ser Arg Leu His Ser
1 5

<210> 46
<211> 9
<212> PRT
<213> Artificial

<220>
<223> Light chain CDR 3 of 11H2

<400> 46

Gln Gln Gly Lys Thr Leu Pro Arg Thr
1 5

<210> 47
<211> 15
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 1 of 11H2

<400> 47
gactactatg tgaac 15

<210> 48
<211> 51
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 2 of 11H2

<400> 48
gttagtaatc ctaagaacgg tgataaaagt tacaaccaga agttcaaggg c 51

<210> 49
<211> 39
<212> DNA
<213> Artificial

<220>
<223> Heavy chain CDR 3 of 11H2

<400> 49
gggctttact acgctggtac ctacgggtac ttcgatgtc 39

<210> 50
<211> 33
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 1 of 11H2

<400> 50
agggcaagtc aggacattag caattattta aac 33

<210> 51
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 2 of 11H2

<400> 51
tacacatcaa gattacactc a 21

<210> 52
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Light chain CDR 3 of 11H2

<400> 52
caacagggta aaacgcttcc tcggacg 27

<210> 53
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Generalized Amino Acid Sequences of Complementary Determining Regions of 5G7 and 2H6 (Heavy chain CDR 1)

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<400> 53

Ser His Asn Xaa His
1 5

<210> 54
<211> 17
<212> PRT
<213> Artificial

<220>
<223> Generalized Amino Acid Sequences of Complementary Determining Regions of 5G7 and 2H6 (Heavy chain CDR 2)

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<400> 54

Ala Ile Tyr Pro Gly Xaa Gly Asn Thr Xaa Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> 55
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Generalized Amino Acid Sequences of Complementary Determining Regions of 5G7 and 2H6 (Heavy chain CDR 3)

<400> 55

Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val

1 5 10

<210> 56
<211> 16
<212> PRT
<213> Artificial

<220>
<223> Generalized Amino Acid Sequences of Complementary Determining Regions of 5G7 and 2H6 (Light chain CDR 1)

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<400> 56

Arg Ser Ser Xaa Xaa Leu Val His Xaa Asn Gly Asn Thr Tyr Leu His
1 5 10 15

<210> 57
<211> 7
<212> PRT
<213> Artificial

<220>
<223> Generalized Amino Acid Sequences of Complementary Determining Regions of 5G7 and 2H6 (Light chain CDR 2)

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<400> 57

Xaa Val Ser Xaa Arg Phe Ser
1 5

<210> 58
<211> 9
<212> PRT

<213> Artificial

<220>
<223> Generalized Amino Acid Sequences of Complementary Determining Regions of 5G7 and 2H6 (Light chain CDR 3)

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

<400> 58

Ser Gln Ser Thr Xaa Val Pro Trp Thr
1 5

<210> 59
<211> 447
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK1)

<400> 59

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
20 25 30

Asn Leu His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asn Thr Ala Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

```
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
                165                 170                 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
            180                 185                 190

Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His
        195                 200                 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
    210                 215                 220

Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Ala Ala Ala Pro Ser Val
225                 230                 235                 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
                245                 250                 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
            260                 265                 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
        275                 280                 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser
    290                 295                 300

Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305                 310                 315                 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
                325                 330                 335

Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
            340                 345                 350

Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
        355                 360                 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
    370                 375                 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
385                 390                 395                 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
                405                 410                 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
            420                 425                 430
```

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 60
<211> 121
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK1) variable region

<400> 60

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
20 25 30

Asn Leu His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asn Thr Ala Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 61
<211> 1344
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK1)

<400> 61
caggtgcagc tggtgcagtc tggagccgaa gtgaagaaac caggggcctc tgtcaaggtg 60

agttgcaagg cctccggtta cactttcacc tcccacaacc tgcattgggt gagacaggct 120

cctggacagc gactggagtg gatgggagca atctacccag gcaacggaaa tactgcctat 180

aatcagaagt ttaaaggcag ggtgacaatt actcgggaca cttccgcaag caccgcctac 240

atggagctgt ccagcctgag gagtgaagat accgctgtgt actattgtgc acgatgggga 300

tccgtggtcg gagactggta tttcgatgtg tgggggcagg gtaccctggt cacagtgtct 360

agtgcctcca caaagggccc agcgtgttt ccactggctc cctgctctag gagtacatca 420

gagtccactg ccgctctggg atgtctggtg aaggactatt tccctgaacc agtcaccgtg 480

agttggaact caggggctct gacatctggt gtccacactt ttcctgcagt gctgcagtca 540

tccggcctgt actccctgag ctctgtggtc acagtcccaa gttcaaattt cggaacccag 600

acatatactt gcaacgtgga ccataagccc agcaatacca aggtcgataa aacagtggag 660

cgaaagtgct gtgtcgaatg cccaccttgt ccagctccac cagcagcagc tccttctgtg 720

ttcctgtttc ctccaaagcc aaaagacact ctgatgatca gccggacccc cgaggtcaca 780

tgtgtggtcg tggacgtgtc tcacgaggat cctgaagtcc agtttaactg gtacgtggat 840

ggggtcgaag tgcataatgc aaagacaaaa ccacgagagg aacagttcaa ctctacattt 900

cgtgtcgtga gtgtgctgac tgtcgtgcac caggattggc tgaacggcaa ggagtataag 960

tgcaaagtgt ccaataaggg actgcccgcc cctatcgaga aaactattag caagaccaaa 1020

ggccagccta gagaaccaca ggtgtacacc ctgcccccta gtcgcgagga aatgactaag 1080

aaccaggtct cactgacctg tctggtgaaa gggttctatc ccagcgacat tgccgtggag 1140

tgggaatcta atggtcagcc tgagaacaat tacaagacca caccacccat gctggactcc 1200

gatgggagct tctttctgta ttcaaagctg accgtggata aatccaggtg gcagcagggt 1260

aatgtcttta gctgctctgt gatgcacgaa gccctgcaca accattacac tcagaagtcc 1320

ctgtccctgt cacctggaaa gtga 1344

<210> 62
<211> 363
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK1) variable region

<400> 62
caggtgcagc tggtgcagtc tggagccgaa gtgaagaaac caggggcctc tgtcaaggtg 60

agttgcaagg cctccggtta cactttcacc tcccacaacc tgcattgggt gagacaggct 120

cctggacagc gactggagtg gatgggagca atctacccag gcaacggaaa tactgcctat 180

aatcagaagt ttaaaggcag ggtgacaatt actcgggaca cttccgcaag caccgcctac 240

atggagctgt ccagcctgag gagtgaagat accgctgtgt actattgtgc acgatgggga 300

tccgtggtcg gagactggta tttcgatgtg tgggggcagg gtaccctggt cacagtgtct 360

agt 363

<210> 63
<211> 447
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK5)

<400> 63

```
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                  10                  15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
            20                  25                  30

Asn Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45

Gly Ala Ile Tyr Pro Gly Asn Gly Asn Thr Ala Tyr Asn Gln Lys Phe
    50                  55                  60

Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
        115                 120                 125

Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
    130                 135                 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145                 150                 155                 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
                165                 170                 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
            180                 185                 190

Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His
        195                 200                 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
    210                 215                 220

Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Ala Ala Ala Pro Ser Val
225                 230                 235                 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
                245                 250                 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
```

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser
290 295 300

Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335

Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350

Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 64
<211> 121
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK5) variable region

<400> 64

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
20 25 30

Asn Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asn Thr Ala Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Trp Gly Ser Val Val Gly Asp Trp Tyr Phe Asp Val Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 65
<211> 1344
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK5)

<400> 65
caggtgcagc tggtgcagtc tggggccgaa gtgaagaaac caggggcttc tgtcaaggtg 60

agttgcaaag catcaggtta cactttcacc tcccacaacc tgcattgggt gcgacaggct 120

cctggacagg gactggagtg gatgggagca atctacccag ggaacggtaa taccgcttat 180

aatcagaagt ttaaaggcag ggtcacaatg actcgggaca cctccacaag cactgtgtac 240

atggagctgt ccagcctgcg aagtgaagat acagcagtgt actattgtgc acgttgggga 300

tccgtggtcg gtgactggta tttcgatgtg tggggccagg gaaccctggt cacagtgtct 360

agtgcttcca ctaaggggcc cagcgtgttt ccactggcac cctgctctcg gagtacttca 420

gagtccaccg ccgctctggg ctgtctggtg aaggactatt tccctgaacc agtcacagtg 480

agttggaact caggcgcact gacttctgga gtccacacct ttcctgccgt gctgcagtca 540

tccggcctgt actccctgag ctctgtggtc actgtcccaa gttcaaattt cggaacccag 600

acatatactt gcaacgtgga ccataagccc agcaatacaa aggtcgataa aactgtggag 660

agaaagtgct gtgtggaatg cccaccttgt ccagcaccac cagcagcagc tccttctgtg 720

ttcctgtttc ctccaaagcc aaaagacaca ctgatgatca gccgcacacc cgaggtcact 780

tgtgtggtcg tggacgtgtc tcacgaggat cctgaagtcc agtttaactg gtacgtggat 840

ggcgtcgaag tgcataatgc caagaccaaa ccaagagagg aacagttcaa ctctactttt 900

cgcgtcgtga gtgtgctgac cgtcgtgcac caggattggc tgaacggcaa ggagtataag 960

tgcaaagtgt ccaataaggg actgcccgct cctatcgaga aaaccattag caagacaaaa 1020

ggacagccta gggaaccaca ggtgtacacc ctgccccta gtcgggagga aatgaccaag 1080

aaccaggtct cactgacatg tctggtgaaa gggttctatc ccagcgacat tgccgtggag 1140

tgggaatcta atggtcagcc tgagaacaat tacaagacca caccacccat gctggactcc 1200

gatggcagct tctttctgta ttcaaagctg accgtggata aatccaggtg gcagcaggga 1260

aatgtcttta gctgctctgt gatgcacgaa gcactgcata atcactacac tcagaagagc 1320

ctgtccctgt cacctggtaa atga 1344

<210> 66
<211> 363
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Heavy Chain (HK5) variable region

<400> 66
caggtgcagc tggtgcagtc tggggccgaa gtgaagaaac caggggcttc tgtcaaggtg 60

agttgcaaag catcaggtta cactttcacc tcccacaacc tgcattgggt gcgacaggct 120

cctggacagg gactggagtg gatgggagca atctacccag ggaacggtaa taccgcttat 180

aatcagaagt ttaaaggcag ggtcacaatg actcgggaca cctccacaag cactgtgtac 240

atggagctgt ccagcctgcg aagtgaagat acagcagtgt actattgtgc acgttgggga 300

tccgtggtcg gtgactggta tttcgatgtg tggggccagg gaaccctggt cacagtgtct 360

agt 363

<210> 67
<211> 219
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L2)

<400> 67

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Leu Gly Leu Val His Arg
20 25 30

Asn Gly Asn Thr Tyr Leu His Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Leu Leu Ile Tyr Lys Val Ser His Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
85 90 95

```
Thr His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
            100                 105                 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
        115                 120                 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
    130                 135                 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145                 150                 155                 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
                165                 170                 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
            180                 185                 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
        195                 200                 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
    210                 215
```

<210> 68
<211> 112
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L2) variable region

<400> 68

```
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1               5                   10                  15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Leu Gly Leu Val His Arg
            20                  25                  30

Asn Gly Asn Thr Tyr Leu His Trp Phe Gln Gln Arg Pro Gly Gln Ser
        35                  40                  45

Pro Arg Leu Leu Ile Tyr Lys Val Ser His Arg Phe Ser Gly Val Pro
    50                  55                  60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
                85                  90                  95
```

Thr His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 69
<211> 660
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L2)

<400> 69
gatgtcgtga tgacccagtc tcctctgagc ctgcctgtga ctctgggcca gccagcatca 60

atctcctgcc gatccagcct gggactggtg caccgtaacg ggaataccta cctgcattgg 120

ttccagcaga ggcctggtca gagtccccgg ctgctgatct ataaggtgtc tcacagattc 180

agtggcgtcc cagaccgctt tagcggctct ggaagtggga ctgatttcac cctgaaaatt 240

tcccgagtgg aggcagaaga cgtgggagtc tactattgct cacagtccac acatgtgccc 300

tggacttttg gtcagggcac caaggtcgag atcaaacgca ccgtggccgc tcctagcgtc 360

ttcatttttc ccccttctga cgaacagctg aagtcaggaa cagcttccgt ggtctgtctg 420

ctgaacaatt tttaccccag agaggcaaag gtgcagtgga aagtcgataa cgccctgcag 480

agcggcaact cccaggagag tgtgacagaa caggactcaa aggattccac ttatagcctg 540

tctagtaccc tgacactgtc taaagctgat tacgagaagc acaaagtgta tgcatgtgaa 600

gtcacccacc aggggctgtc atcacccgtc accaagtcct ttaatagagg ggagtgttga 660

<210> 70
<211> 336
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L2) variable region

<400> 70
gatgtcgtga tgacccagtc tcctctgagc ctgcctgtga ctctgggcca gccagcatca 60

atctcctgcc gatccagcct gggactggtg caccgtaacg ggaataccta cctgcattgg 120

ttccagcaga ggcctggtca gagtccccgg ctgctgatct ataaggtgtc tcacagattc 180

agtggcgtcc cagaccgctt tagcggctct ggaagtggga ctgatttcac cctgaaaatt 240

tcccgagtgg aggcagaaga cgtgggagtc tactattgct cacagtccac acatgtgccc 300

tggacttttg gtcagggcac caaggtcgag atcaaa 336

<210> 71
<211> 219
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L5)

<400> 71

```
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1               5                  10                  15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Leu Gly Leu Val His Arg
            20                  25                  30

Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45

Pro Gln Leu Leu Ile Tyr Lys Val Ser His Arg Phe Ser Gly Val Pro
    50                  55                  60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
                85                  90                  95

Thr His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
            100                 105                 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
        115                 120                 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
    130                 135                 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145                 150                 155                 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
                165                 170                 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
            180                 185                 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
        195                 200                 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
    210                 215
```

<210> 72
<211> 112
<212> PRT
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L5) variable Region

<400> 72

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Leu Gly Leu Val His Arg
20 25 30

Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser His Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
85 90 95

Thr His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 73
<211> 660
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L5)

<400> 73
gatattgtga tgactcagac tccactgagc ctgccagtga ctcccggcca gcctgcatca 60

atctcctgca gatccagcct gggactggtg caccgcaacg ggaataccta cctgcattgg 120

tatctgcaga agcctggtca gagtccccag ctgctgatct acaaagtgtc tcacaggttc 180

agtggcgtcc ccgaccggtt tagcggctct ggaagtggga ctgatttcac cctgaagatt 240

tcccgagtgg aggccgaaga cgtgggcgtc tactattgct cacagtccac acatgtgcct 300

tggacttttg gtcagggcac caaggtcgag atcaaaagga ccgtggccgc tccaagcgtc 360

ttcatttttc ccccttctga cgaacagctg aagtcaggaa cagcttccgt ggtctgtctg 420

ctgaacaatt tctaccccag agaggcaaag gtgcagtgga aagtcgataa cgccctgcag 480

agcggcaact cccaggagag tgtgacagaa caggactcaa aggattccac ttatagcctg 540

tctagtaccc tgacactgtc taaagctgat tacgagaagc acaaagtgta tgcatgtgaa 600

gtcacacacc agggtctgag ttcccccgtc accaaatcct ttaatcgtgg agagtgctga 660

<210> 74
<211> 336
<212> DNA
<213> Artificial

<220>
<223> Humanized Anti-Human XCR1 Antibody Light Chain (L5) variable Region

<400> 74
gatattgtga tgactcagac tccactgagc ctgccagtga ctcccggcca gcctgcatca 60

atctcctgca gatccagcct gggactggtg caccgcaacg ggaataccta cctgcattgg 120

tatctgcaga agcctggtca gagtccccag ctgctgatct acaaagtgtc tcacaggttc 180

agtggcgtcc ccgaccggtt tagcggctct ggaagtggga ctgatttcac cctgaagatt 240

tcccgagtgg aggccgaaga cgtgggcgtc tactattgct cacagtccac acatgtgcct 300

tggacttttg gtcagggcac caaggtcgag atcaaa 336

<210> 75
<211> 57
<212> DNA
<213> Artificial

<220>
<223> Signal sequence

<400> 75
atgggattca gcaggatctt tctcttcctc ctgtcagtaa ctacaggtgt ccactcc 57

<210> 76
<211> 57
<212> DNA
<213> Artificial

<220>
<223> Signal sequence

<400> 76
atgaagttgc ctgttaggct gttggtgctg ctgttctggt ttcctgcttc caacact 57

<210> 77
<211> 57
<212> DNA
<213> Artificial

<220>
<223> Signal sequence

<400> 77
atggaatggt catgggtctt tctgttcttt ctgagtgtca caaccggggt gcatagc 57

<210> 78
<211> 57
<212> DNA
<213> Artificial

<220>
<223> Signal sequence

<400> 78
atggaatggt cttgggtctt tctgttcttt ctgtccgtca ctaccggggt ccactct 57

<210> 79
<211> 60
<212> DNA
<213> Artificial

<220>
<223> Signal sequence

<400> 79
atgtccgtgc ctactcaggt gctggggctg ctgctgctgt ggctgaccga tgctcgttgc 60

<210> 80
<211> 60
<212> DNA
<213> Artificial

<220>
<223> Signal sequence

<400> 80
atgtccgtgc ctactcaggt gctggggctg ctgctgctgt ggctgaccga tgctcgttgt 60

<210> 81
<211> 12
<212> DNA
<213> Artificial

<220>
<223> 5' adaptor ad29S

<400> 81
acatcactcc gt 12

<210> 82
<211> 50
<212> DNA
<213> Artificial

<220>
<223> 5' adaptor obtained 29AS

<400> 82
acggagtgat gtccgtcgac gtatctctgc gttgatactt cagcgtagct 50

<210> 83
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 83
agctacgctg aagtatcaac gcagag 26

<210> 84
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 84
aggacagggg ttgattgttg a 21

<210> 85

<211> 26
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 85
ctcaagtttt ttgtccaccg tggtgc 26

<210> 86
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 86
ctcaattttc ttgtccacct tggtgc 26

<210> 87
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 87
gccagtggat agactgatg 19

<210> 88
<211> 27
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 88
ctcattcctg ttgaagctct tgacaat 27

<210> 89
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 89
gatggataca gttggtgcag c 21

<210> 90
<211> 24
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 90

cagatcctca gcctccactc tgct 24

<210> 91
<211> 333
<212> PRT
<213> Abramis brama

<400> 91

Met Glu Ser Ser Gly Asn Pro Glu Ser Thr Thr Phe Phe Tyr Tyr Asp
1 5 10 15

Leu Gln Ser Gln Pro Cys Glu Asn Gln Ala Trp Val Phe Ala Thr Leu
20 25 30

Ala Thr Thr Val Leu Tyr Cys Leu Val Phe Leu Leu Ser Leu Val Gly
35 40 45

Asn Ser Leu Val Leu Trp Val Leu Val Lys Tyr Glu Ser Leu Glu Ser
50 55 60

Leu Thr Asn Ile Phe Ile Leu Asn Leu Cys Leu Ser Asp Leu Val Phe
65 70 75 80

Ala Cys Leu Leu Pro Val Trp Ile Ser Pro Tyr His Trp Gly Trp Val
85 90 95

Leu Gly Asp Phe Leu Cys Lys Leu Leu Asn Met Ile Phe Ser Ile Ser
100 105 110

Leu Tyr Ser Ser Ile Phe Phe Leu Thr Ile Met Thr Ile His Arg Tyr
115 120 125

Leu Ser Val Val Ser Pro Leu Ser Thr Leu Arg Val Pro Thr Leu Arg
130 135 140

Cys Arg Val Leu Val Thr Met Ala Val Trp Val Ala Ser Ile Leu Ser
145 150 155 160

Ser Ile Leu Asp Thr Ile Phe His Lys Val Leu Ser Ser Gly Cys Asp
165 170 175

Tyr Ser Glu Leu Thr Trp Tyr Leu Thr Ser Val Tyr Gln His Asn Leu
180 185 190

Phe Phe Leu Leu Ser Leu Gly Ile Ile Leu Phe Cys Tyr Val Glu Ile
195 200 205

Leu Arg Thr Leu Phe Arg Ser Arg Ser Lys Arg Arg His Arg Thr Val
210 215 220

Lys Leu Ile Phe Ala Ile Val Val Ala Tyr Phe Leu Ser Trp Gly Pro
225 230 235 240

```
Tyr Asn Phe Thr Leu Phe Leu Gln Thr Leu Phe Arg Thr Gln Ile Ile
                245                 250                 255

Arg Ser Cys Glu Ala Lys Gln Gln Leu Glu Tyr Ala Leu Leu Ile Cys
            260                 265                 270

Arg Asn Leu Ala Phe Ser His Cys Cys Phe Asn Pro Val Leu Tyr Val
        275                 280                 285

Phe Val Gly Val Lys Phe Arg Thr His Leu Lys His Val Leu Arg Gln
    290                 295                 300

Phe Trp Phe Cys Arg Leu Gln Ala Pro Ser Pro Ala Ser Ile Pro His
305                 310                 315                 320

Ser Pro Gly Ala Phe Ala Tyr Glu Gly Ala Ser Phe Tyr
                325                 330
```

<210> 92
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 92

```
Met Glu Ser Ser Gly Asn Pro Glu Ser Thr Thr Phe
1               5                   10
```

<210> 93
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 93

```
Ser Ser Gly Asn Pro Glu Ser Thr Thr Phe Phe Tyr
1               5                   10
```

<210> 94
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 94

```
Gly Asn Pro Glu Ser Thr Thr Phe Phe Tyr Tyr Asp
1               5                   10
```

<210> 95
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 95

Pro Glu Ser Thr Thr Phe Phe Tyr Tyr Asp Leu Gln
1 5 10

<210> 96
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 96

Ser Thr Thr Phe Phe Tyr Tyr Asp Leu Gln Ser Gln
1 5 10

<210> 97
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 97

Thr Phe Phe Tyr Tyr Asp Leu Gln Ser Gln Pro Cys
1 5 10

<210> 98
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 98

Phe Tyr Tyr Asp Leu Gln Ser Gln Pro Cys Glu Asn
1 5 10

<210> 99
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 99

Tyr Asp Leu Gln Ser Gln Pro Cys Glu Asn Gln Ala
1 5 10

<210> 100
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 100

Leu Gln Ser Gln Pro Cys Glu Asn Gln Ala Trp Val
1 5 10

<210> 101
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 101

Ser Gln Pro Cys Glu Asn Gln Ala Trp Val Phe Ala
1 5 10

<210> 102
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 102

Pro Cys Glu Asn Gln Ala Trp Val Phe Ala Thr Leu
1 5 10

<210> 103
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 103

Glu Asn Gln Ala Trp Val Phe Ala Thr Leu Ala Thr
1 5 10

<210> 104
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 104

Gln Ala Trp Val Phe Ala Thr Leu Ala Thr Thr Val
1 5 10

<210> 105
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 105

Ile Ser Pro Tyr His Trp Gly Trp Val Leu Gly Asp
1 5 10

<210> 106
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 106

Tyr His Trp Gly Trp Val Leu Gly Asp Phe Leu Cys
1 5 10

<210> 107
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 107

Gly Trp Val Leu Gly Asp Phe Leu Cys Lys Leu Leu
1 5 10

<210> 108
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 108

Ile Phe His Lys Val Leu Ser Ser Gly Cys Asp Tyr
1 5 10

<210> 109
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 109

Lys Val Leu Ser Ser Gly Cys Asp Tyr Ser Glu Leu
1 5 10

<210> 110
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 110

Ser Ser Gly Cys Asp Tyr Ser Glu Leu Thr Trp Tyr
1 5 10

<210> 111
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 111

Cys Asp Tyr Ser Glu Leu Thr Trp Tyr Leu Thr Ser
1 5 10

<210> 112
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 112

Ser Glu Leu Thr Trp Tyr Leu Thr Ser Val Tyr Gln
1 5 10

<210> 113
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 113

Leu Gln Thr Leu Phe Arg Thr Gln Ile Ile Arg Ser
1 5 10

<210> 114
<211> 12
<212> PRT
<213> Artificial

<220>

<223> Peptide_extracellular region

<400> 114

Leu Phe Arg Thr Gln Ile Ile Arg Ser Cys Glu Ala
1 5 10

<210> 115
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 115

Thr Gln Ile Ile Arg Ser Cys Glu Ala Lys Gln Gln
1 5 10

<210> 116
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 116

Ile Arg Ser Cys Glu Ala Lys Gln Gln Leu Glu Tyr
1 5 10

<210> 117
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Peptide_extracellular region

<400> 117

Cys Glu Ala Lys Gln Gln Leu Glu Tyr Ala Leu Leu
1 5 10

<210> 118
<211> 24
<212> PRT
<213> Artificial

<220>
<223> Candidate epitope

<400> 118

Pro Glu Ser Thr Thr Phe Phe Tyr Tyr Asp Leu Gln Ser Gln Pro Cys
1 5 10 15

Glu Asn Gln Ala Trp Val Phe Ala
20

<210> 119
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Candidate epitope

<400> 119

Cys Asp Tyr Ser Glu Leu Thr Trp Tyr Leu Thr Ser
1 5 10